Archive
SickKids Scientist Dr. Adam Shlien Secures $6 Million To Advance Cancer Diagnostic Platform
SickKids Scientist Dr. Adam Shlien Secures $6 Million To Advance Cancer Diagnostic Platform Dr. Adam Shlien, a Senior Scientist in the Genetics & Genome Biology program at The Hospital for Sick Children (SickKids), has been awarded $6 million to advance his ground-breaking cancer diagnostic platform toward clinical implementation. The funding comes as part of Genome Canada’s Genomic Applications Partnership Program (GAPP). Shlien’s innovative machine-learning driven universal tumour classifier was developed at SickKids and has the capability to swiftly analyze and classify over 90 per cent of sarcomas – a particularly challenging [...]
Exploring Immune Responses in Type One Diabetes Onset
Exploring Immune Responses in Type One Diabetes Onset Research led by Dr. Jayne Danska, Senior Scientist in the Genetics and Genome Biology program at The Hospital for Sick Children (SickKids), suggests that immune responses to specific gut bacteria could predict the development of type one diabetes (T1D) and the effectiveness of teplizumab, an immunotherapy treatment recently approved in the USA for delaying T1D onset. By exploring the influence of the gut microbiome on immune responses in children at risk for T1D, this research identified patterns in antibody responses linked to the [...]
Radiant Biotherapeutics Secures $2M Grant for Next-Gen HIV Biologics
Radiant Biotherapeutics Secures $2M Grant for Next-Gen HIV Biologics Industry Partnerships & Commercialization (IP&C) at The Hospital for Sick Children (SickKids) is pleased to share that Radiant Biotherapeutics, a biotechnology start-up based on a foundational IP from the lab of Dr. Jean-Philippe Julien at SickKids and Dr. Bebhinn Teanor at the University of Toronto, has secured a $2M grant from the Bill & Melinda Gates Foundation. This generous funding will catalyze a transformative two-year project focused on the development of next-generation HIV biologics using Radiant’s antibody technology platform – Multabody, which [...]
Accelerating Innovation: IP&C’s Eighth Annual Proof of Principle Competition Awards $300,000 to Outstanding SickKids’ Projects
Accelerating Innovation: IP&C's Eighth Annual Proof of Principle Competition Awards $300,000 to Outstanding SickKids' Projects From exploring innovative approaches for epilepsy treatment, to introducing a device that could transform how specimens are collected from the gastrointestinal tract, this year's Proof of Principle (PoP) Grant Competition highlighted pioneering advancements in research at The Hospital for Sick Children (SickKids). Sponsored by Industry Partnerships & Commercialization (IP&C), PoP provides SickKids innovators with gap funding that can propel their research discoveries and inventions toward commercially viable products or services to benefit patients. A collaborative approach [...]
A designer peptide against the EAG2–Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma
Breaking new ground in glioblastoma research: A designer peptide against the EAG2–Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma Years of research into the molecular mechanisms behind glioblastoma, a highly lethal brain cancer with limited treatment options, have sparked a ground-breaking discovery at The Hospital for Sick Children (SickKids) – a designer peptide targeting the EAG2-Kvβ2 protein-protein interaction, which has shown promising therapeutic efficacy in preclinical models. Recognizing the potential of this designer peptide to transform glioblastoma treatment, SickKids’ Industry Partnerships & Commercialization (IP&C) office [...]
